RBC maintains ZOLL Medical at outperform

ZOLL Medical Corp. was kept at its outperform rating, above average risk, by RBC Capital Markets analyst Phil Nalbone after the company reported better-than-expected fiscal third-quarter sales and earnings. Even without considering a $5 million order by the U.S. military, ZOLL's revenue for the quarter beat RBC's estimates by $1 million, according to the analyst. RBC raised its sales forecast by $12.18, million to $272.5 million and its earnings-per-share estimate by 4 cents to $1.32. Shares of the Chelmsford, Mass.-based medical device company were up 53 cents, or 1.56%, at $34.47 on volume of 234,439 shares versus the three-month running average of 151,559 shares. (Nasdaq: ZOLL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.